Dec 22, 2008 - EPIX Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced that the U.S. FDA has approved for marketing its novel blood pool magnetic resonance angiography agent, Vasovist (gadofosveset trisodium), to evaluate aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease.
The details can be read here.
No comments:
Post a Comment